2024 Q3 Form 10-Q Financial Statement
#000143774924026451 Filed on August 13, 2024
Income Statement
| Concept | 2024 Q3 | 2024 Q2 | 2023 Q2 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $1.662M | $1.799M | |
| YoY Change | 22.95% | ||
| % of Gross Profit | |||
| Research & Development | $1.174M | $954.0K | $368.0K |
| YoY Change | 50.02% | 159.24% | |
| % of Gross Profit | |||
| Depreciation & Amortization | $45.00K | $43.00K | $0.00 |
| YoY Change | |||
| % of Gross Profit | |||
| Operating Expenses | $2.836M | $2.753M | $871.0K |
| YoY Change | -57.61% | 216.07% | |
| Operating Profit | -$2.836M | -$2.753M | -$871.0K |
| YoY Change | -51.27% | 216.07% | |
| Interest Expense | $29.00K | $54.00K | |
| YoY Change | 18.13% | ||
| % of Operating Profit | |||
| Other Income/Expense, Net | $29.00K | $54.00K | $6.000K |
| YoY Change | -112.11% | 800.0% | |
| Pretax Income | -$2.807M | -$2.699M | -$865.0K |
| YoY Change | -59.35% | 212.02% | |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$2.807M | -$2.700M | -$865.0K |
| YoY Change | -53.53% | 212.14% | 153.67% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | -$2.47 | -$0.14 | -$0.07 |
| Diluted Earnings Per Share | -$2.47 | -$0.14 | |
| COMMON SHARES | |||
| Basic Shares Outstanding | 23.04M | 18.85M | 12.88M |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2024 Q3 | 2024 Q2 | 2023 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $5.155M | $6.751M | |
| YoY Change | 140.29% | ||
| Cash & Equivalents | $5.200M | $6.800M | $2.939M |
| Short-Term Investments | |||
| Other Short-Term Assets | $199.0K | $325.0K | |
| YoY Change | 219.42% | ||
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $5.354M | $7.076M | |
| YoY Change | 142.51% | ||
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $17.00K | $19.00K | |
| YoY Change | |||
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | |||
| YoY Change | |||
| Total Long-Term Assets | $17.00K | $19.00K | |
| YoY Change | -89.54% | ||
| TOTAL ASSETS | |||
| Total Short-Term Assets | $5.354M | $7.076M | |
| Total Long-Term Assets | $17.00K | $19.00K | |
| Total Assets | $5.371M | $7.095M | |
| YoY Change | 126.6% | ||
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $574.0K | $287.0K | |
| YoY Change | 42.47% | ||
| Accrued Expenses | $683.0K | $476.0K | |
| YoY Change | 1873.99% | ||
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $1.257M | $763.0K | |
| YoY Change | 187.31% | ||
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $1.086M | $1.043M | |
| YoY Change | 1660.13% | ||
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $1.086M | $1.043M | |
| YoY Change | -77.64% | ||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $1.257M | $763.0K | |
| Total Long-Term Liabilities | $1.086M | $1.043M | |
| Total Liabilities | $2.343M | $1.806M | |
| YoY Change | -55.75% | ||
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$44.50M | -$41.70M | |
| YoY Change | |||
| Common Stock | $1.000K | $19.00K | |
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $3.028M | $5.289M | $2.619M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $5.371M | $7.095M | |
| YoY Change | 126.6% |
Cashflow Statement
| Concept | 2024 Q3 | 2024 Q2 | 2023 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$2.807M | -$2.700M | -$865.0K |
| YoY Change | -53.53% | 212.14% | 153.67% |
| Depreciation, Depletion And Amortization | $45.00K | $43.00K | $0.00 |
| YoY Change | |||
| Cash From Operating Activities | -$1.596M | -$1.900M | -$700.0K |
| YoY Change | -11.54% | 171.43% | |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $0.00 | $5.000K | $0.00 |
| YoY Change | |||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | $0.00 | -$5.000K | $0.00 |
| YoY Change | |||
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 0.000 | $0.00 | $2.735M |
| YoY Change | -100.0% | -100.0% | |
| NET CHANGE | |||
| Cash From Operating Activities | -1.596M | -$1.900M | -$700.0K |
| Cash From Investing Activities | 0.000 | -$5.000K | $0.00 |
| Cash From Financing Activities | 0.000 | $0.00 | $2.735M |
| Net Change In Cash | -1.596M | -$1.857M | $2.074M |
| YoY Change | -224.62% | -189.54% | |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$1.596M | -$1.900M | -$700.0K |
| Capital Expenditures | $0.00 | $5.000K | $0.00 |
| Free Cash Flow | -$1.596M | -$1.905M | -$700.0K |
| YoY Change | 172.14% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
10839148 | |
| CY2023Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7503529 | |
| CY2024Q2 | us-gaap |
Advertising Expense
AdvertisingExpense
|
100000 | usd |
| CY2023Q2 | us-gaap |
Advertising Expense
AdvertisingExpense
|
100000 | usd |
| CY2024Q2 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;"><i>Correction of an Immaterial Error in the Prior Period Financial Statements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">During the <em style="font: inherit;">fourth</em> quarter of fiscal <em style="font: inherit;">2024</em> (<em style="font: inherit;"> March 31, 2024), </em>the Company determined that the prior year financial statements had an error caused by an immaterial classification error of certain research and development expense in accordance with ASC <em style="font: inherit;">730</em> Research and Development Costs. As a result, certain prior year amounts have been revised for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period financial statements in accordance with <i>SEC Staff Accounting Bulletin <em style="font: inherit;">No.</em> <em style="font: inherit;">99</em></i>, “<i>Materiality</i>,” (<i>ASC Topic <em style="font: inherit;">250,</em> Accounting Changes and Error Corrections</i>). Based on this assessment, the Company concluded that these classification error corrections in its Statements of Operations are <em style="font: inherit;">not</em> material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had <em style="font: inherit;">no</em> impact on the fiscal year <em style="font: inherit;">2023</em> Balance Sheet, Statements of Cash Flows, or Statement of Changes in Stockholders’ Equity. Further, the immaterial corrections did <em style="font: inherit;">not</em> result in a change in operating losses, net loss, or basic or diluted earnings per share in the Income Statement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 16pt; text-indent: 0pt;">A summary of immaterial corrections reflecting the prior period impact to the Company’s Statement of Operations, for the quarter ended <em style="font: inherit;"> June 30, 2023</em> is shown below (in thousands):</p> <p style="margin: 0pt; font-family: "Times New Roman"; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">As Revised</em></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">June 30, 2023</em></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Correction</em></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">June 30, 2023</em></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative expense</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">523</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">503</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expense</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">348</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">368</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">871</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">871</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> | |
| CY2024Q2 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2024Q2 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--03-31 | |
| CY2024Q2 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2024Q2 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2024 | |
| CY2024Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
| CY2024Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
| CY2024Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2024Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2024Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2024Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2024Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2024Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2024Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
500000000 | |
| CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
500000000 | |
| CY2024Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
19242081 | |
| CY2024Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
19242081 | |
| CY2024Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
18846094 | |
| CY2024Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
18846094 | |
| CY2024Q2 | us-gaap |
Revenues
Revenues
|
0 | usd |
| CY2023Q2 | us-gaap |
Revenues
Revenues
|
0 | usd |
| CY2024Q2 | amix |
Payments For Initial Public Offering Issuance Costs
PaymentsForInitialPublicOfferingIssuanceCosts
|
0 | usd |
| CY2024Q2 | us-gaap |
Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
|
P3Y | |
| CY2023Q2 | us-gaap |
Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
|
0 | usd |
| CY2024Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2023Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2024Q2 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | pure |
| CY2023Q2 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | pure |
| CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2023Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2024Q2 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
| CY2024Q2 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q2 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
| CY2024Q2 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
| CY2024Q2 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2024Q2 | dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | |
| CY2024Q2 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2024-06-30 | |
| CY2024Q2 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
| CY2024Q2 | dei |
Entity File Number
EntityFileNumber
|
001-41940 | |
| CY2024Q2 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
| CY2024Q2 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
47-1607810 | |
| CY2024Q2 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
21 Waterway Avenue, Suite 300 | |
| CY2024Q2 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
The Woodlands | |
| CY2024Q2 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
TX | |
| CY2024Q2 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
77380 | |
| CY2024Q2 | dei |
City Area Code
CityAreaCode
|
713 | |
| CY2024Q2 | dei |
Local Phone Number
LocalPhoneNumber
|
588-6150 | |
| CY2024Q2 | dei |
Security12b Title
Security12bTitle
|
Common Stock, $0.001 par value | |
| CY2024Q2 | dei |
Trading Symbol
TradingSymbol
|
AMIX | |
| CY2024Q2 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
| CY2024Q2 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2024Q2 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
| CY2024Q2 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2024Q2 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2024Q2 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | |
| CY2024Q2 | dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | |
| CY2024Q2 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2024Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
23036933 | |
| CY2024Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
6751000 | usd |
| CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
8608000 | usd |
| CY2024Q2 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
325000 | usd |
| CY2024Q1 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
783000 | usd |
| CY2024Q2 | us-gaap |
Assets Current
AssetsCurrent
|
7076000 | usd |
| CY2024Q1 | us-gaap |
Assets Current
AssetsCurrent
|
9391000 | usd |
| CY2024Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
19000 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
16000 | usd |
| CY2024Q2 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
19000 | usd |
| CY2024Q1 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
16000 | usd |
| CY2024Q2 | us-gaap |
Assets
Assets
|
7095000 | usd |
| CY2024Q1 | us-gaap |
Assets
Assets
|
9407000 | usd |
| CY2024Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
287000 | usd |
| CY2024Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
492000 | usd |
| CY2024Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
476000 | usd |
| CY2024Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
285000 | usd |
| CY2024Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
763000 | usd |
| CY2024Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
777000 | usd |
| CY2024Q2 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
1043000 | usd |
| CY2024Q1 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
1002000 | usd |
| CY2024Q2 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
1043000 | usd |
| CY2024Q1 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
1002000 | usd |
| CY2024Q2 | us-gaap |
Liabilities
Liabilities
|
1806000 | usd |
| CY2024Q1 | us-gaap |
Liabilities
Liabilities
|
1779000 | usd |
| CY2024Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
| CY2024Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
| CY2024Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
19000 | usd |
| CY2024Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
19000 | usd |
| CY2024Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
46938000 | usd |
| CY2024Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
46578000 | usd |
| CY2024Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-41668000 | usd |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-38969000 | usd |
| CY2024Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
5289000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
7628000 | usd |
| CY2024Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
7095000 | usd |
| CY2024Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
9407000 | usd |
| CY2024Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1799000 | usd |
| CY2023Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
503000 | usd |
| CY2024Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
954000 | usd |
| CY2023Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
368000 | usd |
| CY2024Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
2753000 | usd |
| CY2023Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
871000 | usd |
| CY2024Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2753000 | usd |
| CY2023Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-871000 | usd |
| CY2024Q2 | us-gaap |
Interest Expense Nonoperating
InterestExpenseNonoperating
|
41000 | usd |
| CY2023Q2 | us-gaap |
Interest Expense Nonoperating
InterestExpenseNonoperating
|
-0 | usd |
| CY2024Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
95000 | usd |
| CY2023Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
6000 | usd |
| CY2024Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
54000 | usd |
| CY2023Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
6000 | usd |
| CY2024Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-2699000 | usd |
| CY2023Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-865000 | usd |
| CY2024Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2023Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2024Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2699000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-865000 | usd |
| CY2024Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.14 | |
| CY2023Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.07 | |
| CY2024Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
18902248 | |
| CY2023Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
12884604 | |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
644000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-865000 | usd |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
2840000 | usd |
| CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
2619000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
7628000 | usd |
| CY2024Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2699000 | usd |
| CY2024Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
360000 | usd |
| CY2024Q2 | amix |
Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
|
0 | usd |
| CY2024Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
5289000 | usd |
| CY2024Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2699000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-865000 | usd |
| CY2024Q2 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
360000 | usd |
| CY2023Q2 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
0 | usd |
| CY2024Q2 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
43000 | usd |
| CY2023Q2 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
0 | usd |
| CY2024Q2 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-458000 | usd |
| CY2023Q2 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
25000 | usd |
| CY2024Q2 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-205000 | usd |
| CY2023Q2 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
209000 | usd |
| CY2024Q2 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
191000 | usd |
| CY2023Q2 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
20000 | usd |
| CY2024Q2 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1852000 | usd |
| CY2023Q2 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-661000 | usd |
| CY2024Q2 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
5000 | usd |
| CY2023Q2 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
-0 | usd |
| CY2024Q2 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-5000 | usd |
| CY2023Q2 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
0 | usd |
| CY2024Q2 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | usd |
| CY2023Q2 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
2840000 | usd |
| CY2024Q2 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
-0 | usd |
| CY2023Q2 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
105000 | usd |
| CY2024Q2 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | usd |
| CY2023Q2 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
2735000 | usd |
| CY2024Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-1857000 | usd |
| CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
2074000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
8608000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
865000 | usd |
| CY2024Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
6751000 | usd |
| CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
2939000 | usd |
| CY2024Q2 | us-gaap |
Stock Issued1
StockIssued1
|
4000 | usd |
| CY2023Q2 | us-gaap |
Stock Issued1
StockIssued1
|
0 | usd |
| CY2024Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2700000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-900000 | usd |
| CY2024Q2 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1900000 | usd |
| CY2023Q2 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-700000 | usd |
| CY2024Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-41700000 | usd |
| CY2024Q2 | amix |
Working Capital Deficit
WorkingCapitalDeficit
|
6300000 | usd |
| CY2024Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
6800000 | usd |
| CY2024Q2 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Use of Estimates in Financial Statement Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The preparation of these unaudited condensed interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include work performed but <em style="font: inherit;">not</em> yet billed by contract manufacturers, engineers and research organizations and the valuation of equity related instruments. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"></p> | |
| CY2023Q2 | amix |
Payments For Initial Public Offering Issuance Costs
PaymentsForInitialPublicOfferingIssuanceCosts
|
100000 | usd |
| CY2024Q2 | us-gaap |
Long Term Debt Fair Value
LongTermDebtFairValue
|
1000000 | usd |
| CY2024Q2 | us-gaap |
Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
|
0 | usd |
| CY2024Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
500000 | |
| CY2024Q1 | amix |
Class Of Warrant Or Right Outstanding Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice
|
1 | |
| CY2024 | amix |
Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
|
P4Y5M23D | |
| CY2024Q1 | amix |
Class Of Warrant Or Right Aggregate Intrinsic Value Outstanding
ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding
|
1010000 | usd |
| CY2024Q2 | amix |
Class Of Warrant Or Right Grants In Period
ClassOfWarrantOrRightGrantsInPeriod
|
0 | |
| CY2024Q2 | amix |
Class Of Warrant Or Right Grants In Period Weighted Average Exercise
ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise
|
0 | |
| CY2024Q2 | amix |
Class Of Warrant Or Right Exercises In Period
ClassOfWarrantOrRightExercisesInPeriod
|
-0 | |
| CY2024Q2 | amix |
Class Of Warrant Or Right Exercises In Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2024Q2 | amix |
Class Of Warrant Or Right Forfeitures In Period
ClassOfWarrantOrRightForfeituresInPeriod
|
-0 | |
| CY2024Q2 | amix |
Class Of Warrant Or Right Forfeitures In Period Weighted Average Exercise Price
ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2024Q2 | amix |
Class Of Warrant Or Right Expirations In Period
ClassOfWarrantOrRightExpirationsInPeriod
|
-0 | |
| CY2024Q2 | amix |
Class Of Warrant Or Right Expirations In Period Weighted Average Exercise Price
ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2024Q2 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
500000 | |
| CY2024Q2 | amix |
Class Of Warrant Or Right Outstanding Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice
|
1 | |
| CY2024Q2 | amix |
Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
|
P4Y2M23D | |
| CY2024Q2 | amix |
Class Of Warrant Or Right Aggregate Intrinsic Value Outstanding
ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding
|
0 | usd |
| CY2024Q2 | amix |
Class Of Warrant Or Right Exercisable Number
ClassOfWarrantOrRightExercisableNumber
|
500000 | |
| CY2024Q2 | amix |
Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
|
1 | |
| CY2024Q2 | amix |
Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm
|
P4Y2M23D | |
| CY2024Q2 | amix |
Class Of Warrant Or Right Aggregate Intrinsic Value Exercisable
ClassOfWarrantOrRightAggregateIntrinsicValueExercisable
|
0 | usd |
| CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
500000000 | |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
23333 | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
3.8 | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
|
942305 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2003600 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
2.33 | |
| CY2024 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P9Y4M6D | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
1680672 | usd |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
2325979 | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.38 | |
| CY2024Q2 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
-0 | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
-0 | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4329579 | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.82 | |
| CY2024Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P9Y6M25D | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
0 | usd |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
321317 | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
2 | |
| CY2024Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P8Y8M8D | |
| CY2024Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
0 | usd |
| CY2024Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
5400000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
|
5744569 | |
| CY2024Q1 | amix |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
|
0.08 | |
| CY2024 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
|
P4Y9M18D | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
|
17072147 | usd |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
|
0 | |
| CY2024Q2 | amix |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
|
397037 | |
| CY2024Q2 | amix |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Exercises In Period Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0.01 | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
|
2963 | |
| CY2024Q2 | amix |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Forfeitures In Period Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
0.01 | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
|
-0 | |
| CY2024Q2 | amix |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Expirations In Period Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
|
5344569 | |
| CY2024Q2 | amix |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
|
0.09 | |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
|
P4Y6M14D | |
| CY2024Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
|
5009401 | usd |
| CY2024Q2 | amix |
Sharebased Compensation Arrangement By Sharebased Payment Award Nonoption Equity Instruments Exercisable Number Outstanding Number
SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber
|
5341236 | |
| CY2024Q2 | amix |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice
|
0.09 | |
| CY2024Q2 | amix |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm
|
P4Y6M14D | |
| CY2024Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
|
5009401 | usd |
